SEATTLE, WA and VANCOUVER, British Columbia, August 1, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2023 financial results on Monday, August 14, 2023, and…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced participation on a panel during the 2023 American Society of Pharmacognosy (ASP) Annual Meeting, being held…
/Read More
Cytisinicline 6- and 12-week dosing schedules, with behavioral support, demonstrated “smoking cessation efficacy and excellent tolerability” Supports potential for cytisinicline to be the first pharmacotherapy approved for smoking cessation in nearly two decades SEATTLE, Wash and VANCOUVER, British Columbia, July 11, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced the publication in JAMA…
/Read More
SEATTLE and VANCOUVER, British Columbia, June 6, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will be presenting at the LD Micro Invitational XIII in Los…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, May 25, 2023 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and…
/Read More